ALK and lung carcinoma: Though the prognostic impact of EGFR mutation, ALK translocation, ROS1 translocation, and BRAF mutations remains controversial in LUAD, targeted therapy remains the best strategy to treat lung cancer patients who harbor these oncogenic driver alterations, which were specifically included in NCCN guideline (5, 30).